Announcements Trials
Browse Landscape

Phase

Phase 2 137Phase 1 43Phase 1/2 17Phase EARLY_PHASE1 9Phase 3 6Phase NA 3Phase 4 3Phase 2/3 2

Status

Recruiting 3Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 31OTHER 6OTHER_GOV 1NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 5Breast 1

Conditions

Ovarian Neoplasms 4Triple Negative Breast Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 182Docetaxel 166Gemcitabine 165Oxaliplatin 162Carboplatin 160Paclitaxel 152Leucovorin 122Drug Therapy 118Dexamethasone 118Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 56Neoadjuvant Therapy 53Lenalidomide 52Letrozole 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × OTHER × olaparib × Clear all
NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NRG Oncology

Phase 3 Recruiting
880 enrolled
Gynecologic

Ovarian Neoplasms

NCT07486687 2026-03-20

PLANET

The Netherlands Cancer Institute

Phase 3 Not yet recruiting
1,000 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
554 enrolled
Gynecologic

Endometrial Neoplasms

NCT05255471 2023-03-24

MITO 35B

National Cancer Institute, Naples

Phase 3 Recruiting
200 enrolled
Gynecologic

Ovarian Neoplasms

NCT03278717 2022-09-27

ICON9

University College, London

Phase 3 Unknown
330 enrolled
Gynecologic

Ovarian Neoplasms

NCT02477644 2022-08-02

PAOLA-1

Arcagy Research

Phase 3 Completed
806 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡